Skip to main content

Table 8 Cost change in the scenario: shift from warfarin to DOAC (2018 prices)

From: Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants

Annual costs in EUR (share % from total costs)Drug retail prices (excl. VAT)Distributor’s drug prices
BaselineScenarioChangeBaselineScenarioChange
Costs of INR monitoring:2,974,840 (59.8)343,500 (6.7)−88.5%2,881,800 (62.9)326,180 (8.2)−88.7%
 INR measurements and medication (N = 4560)2,781,820 (56.0)  2,688,780 (58.7)  
 Time costs of INR monitoring (N = 4560)193,020 (3.8)  193,020 (4.2)  
 Patients unable to switch to DOAC (N = 296) 270,230 (5.3)  264,190 (6.7) 
 Patients not switching to DOAC (<  5 INR M. 2017, N = 553) 73,270 (1.4)  61,990 (1.5) 
Travel costs:815,090 (16.4)97,840 (1.9)−88.0%815,090 (17.8)97,840 (2.5)−88.0%
 Direct travel costs (N = 3961)715,990 (14.4)  715,990 (15.6)  
 Travel time costs (N = 3961)99,100 (2.0)  99,100 (2.2)  
 Patients continuing warfarin (N = 772) 97,840 (1.9)  97,840 (2.5) 
Cost of DOAC therapy:1,181,850 (23.8)4,661,180 (91.4)294.4%883,970 (19.3)3,531,580 (89.3)299.5%
 Patients using DOAC (N = 1239)1,181,850 (23.8)1,181,850 (23.2) 883,970 (19.3)883,970 (22.3) 
 Patients switching from warfarin to DOAC (N = 3711) 3,479,330 (68.2)  2,647,610 (67.0) 
Total cost of anticoagulation management:4,971,780 (100)5,102,520 (100)2.6%4,580,860 (100)3,955,600 (100)−13.6%